Abstract: A system for screening compounds for therapeutic cardiac effects in the cells, tissues and organoids (1) of patients having diseases such as neurological diseases or disorders with significant cardiac comorbidities. The system comprises a medical device apparatus that can be suitable for a single-tier screen for cardio-active compounds that comprises a human ventricular cardiac anisotropic sheet (hvCAS) and human ventricular cardiac tissue strip (hvCTS), a two-tier system further comprising human ventricular cardiac organoid chamber (hvCOC) (20), or a three-tier system still further comprising a medical device comprising multiple organoids (20), which include tissues or organoids (1) of the same or different type (e.g., heart, liver, pancreas, kidney).